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There has been no previous systematic study of bullous 
skin diseases with granular basement membrane zone 
deposition exclusively of C3. In this study we collected 20 
such patients, none of whom showed cutaneous vasculi-
tis histopathologically. Oral dapsone and topical steroids 
were effective. Various serological tests detected no auto-
antibodies or autoantigens. Direct immunofluorescence 
for various complement components revealed deposition 
only of C3 and C5–C9, indicating that no known comple-
ment pathways were involved. Studies of in situ hybridi-
zation and micro-dissection with quantitative RT-PCR 
revealed a slight reduction in expression of C3 in patient 
epidermis. These patients may represent a new disease 
entity, for which we propose the term “granular C3 der-
matosis”. The mechanism for granular C3 deposition in 
these patients is unknown, but it is possible that the con-
dition is caused by autoantibodies to skin or aberrant 
C3 expression in epidermal keratinocytes. Key words: 
basement membrane zone; bullous disease; C3; direct im-
munofluorescence; granular.
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As one of the centres for diagnosis of autoimmune 
bullous diseases (AIBDs) in Japan, we have collected 
sera, frozen skin samples and data for more than 5,000 
patients for whom there was difficulty in diagnosis over a 
period of 20 years. In this large cohort, we found that 20 
patients, some of whom showed dermatitis herpetiformis 
(DH)-like clinical features, showed granular deposition 
of C3, but not immunoglobulin (Ig)A, IgG or IgM, in 
the epidermal basement membrane zone (BMZ) by direct 
immunofluorescence (IF).
Clinically, DH shows pruritic papulo-vesicular skin 
lesions preferentially on the elbows, knees and but-
tocks; histopathologically, neutrophilic microabscesses 
are present in papillary dermis; and immunologically, 
granular deposition of IgA with or without C3 is present 
in papillary dermis (1–4). DH is usually associated with 
coeliac disease in Caucasians (5). DH shows circulating 
IgA antibodies to various antigens, including gliadin 
and endomysium (EMA) (1). However, recent studies 
have shown that patients with DH have pathogenic 
IgA antibodies to epidermal transglutaminase (eTG, 
also called as TG3), as well as IgA antibodies to tissue 
transglutaminase (tTG) (6–10).
There are 3 distinct pathways in activation of com-
plement cascade; i.e. the classical, alternative and lectin 
path ways (11, 12). The classical pathway is activated 
mainly by binding of IgG and IgM antibodies and in-
volves all complement components from C1 to C5–C9. 
The alternative pathway is activated mainly by various 
microbes or IgA antibodies, and involves factor B and 
C5–C9. The lectin pathway is activated mainly by various 
bacteria, dying tissues and mannose-containing sugar 
chains, and involves mannose-binding lectin, ficolins and 
C5–C9. Thus, IgG autoantibodies in various subepider-
mal AIBDs may activate complement via either the clas-
sical or the alternative pathway, while IgA antibodies in 
either DH or linear IgA bullous dermatosis may activate 
complement mainly via the alternative pathway (11, 12).
In this study, we clinically, histopathologically and 
immunologically characterized 20 patients with granu-
lar BMZ deposition exclusively of C3, with particular 
comparison with DH.
The 20 patients showed several common findings in 
terms of clinical and histopathological features, as well 
as a pattern of deposition of complement components 
and production of C3 in epidermis. These findings were 
different from those found in any known AIBDs or other 
inflammatory skin diseases. Therefore, we propose the 
term granular C3 dermatosis (GCD) as a possible new 
disease entity for this condition.
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MATERIALS AND METHODS (for complete details 
see Appendix S11)
Immunofluorescence studies
Indirect IF and complement-fixing IF studies were performed 
as described previously (13, 14). IF studies for various com-
plement components were also performed.
Immunoblot and enzyme-linked immunoassay (ELISA) studies 
for non-dermatitis herpetiformis diseases
Immunoblot analyses of 6 antigen sources were performed as 
described previously (13, 15–20). ELISAs of BP180, BP230, 
Dsg1 and Dsg3 were performed using commercial kits (MBL, 
Nagoya, Japan). IgA ELISA of longer RP of BP180 ectodomain 
was also performed (21).
Serological tests for dermatitis herpetiformis
IgA anti-EMA antibodies were examined as described pre-
viously (22). ELISAs were performed for IgA anti-eTG and 
anti-tTG antibodies (6), IgA anti-eTG antibodies (23), IgA anti-
tTG and anti-gliadin derived peptides (DGP) antibodies (24), 
IgA anti-gliadin antibodies (25) and IgA anti-F-actin antibodies 
(26). The result was evaluated as positive or negative using the 
cut-off value for each ELISA (Table SI1).
In situ hybridization
Specificity and sensitivity of probes used for in situ hybridiza-
tion were confirmed as described previously (27). Immuno-
histochemical in situ hybridization for C3 was performed as 
described previously (28, 29). 28S rRNA probe was used as 
positive control (30).
Micro-dissection and semi-quantitative RT-PCR (qPCR)
Micro-dissection and qPCR were performed as described 
previously (31). Statistical analysis was performed using 
unpaired t-test.
RESULTS
Clinical and histopathological features 
Mean age at onset of skin lesions for the 20 patients, 
10 females and 10 males, was 61.2 years, ranging from 
8 to 83 years. There were no particular or significant 
findings in past histories, complications and given 
drugs. Because there were no gastrointestinal symptoms 
suggesting coeliac disease, no patients underwent endo-
scopic studies for either upper or lower intestinal tracts.
The overall appearance of skin lesions was assessed, 
in particular for the presence of blisters, erythemas and 
eczematous changes (Table SII1). Approximately half 
of the 20 patients showed clinical features, which in 
general mimicked DH; i.e. annular or nummular exu-
dative erythemas, vesicles on peripheries of erythemas 
and eczematous lesions (Fig. 1 a–c), However, some 
patients showed bullous pemphigoid (BP)-like tense 
bullae (Fig. 1 d, e), prurigo-like papular lesions (Fig. 
1f) or annular erythemas without any blisters (Fig. 1 g, 
h). Seven patients showed no apparent blister formation. 
Seventeen patients had severe pruritus. Because of the 
extreme heterogeneity in the skin lesions, times when 
the diagnoses of AIBDs were suspected were variable.
Regarding treatments, oral administrations of various 
corticosteroids, dapsone and combination of minocy-
cline and nicotinamide were used in addition to topical 
corticosteroids. All therapies perfectly or partially 
controlled skin lesions. In general, dapsone could sup-
press the disease completely, although discontinuation 
of dapsone led to recurrence. No patients died during 
follow-up, indicating good prognosis in this condition. 
However, we could not obtain final information about 
therapies and outcome for some patients who had con-
sulted dermatologists in other institutes.
Histopathology and various immunofluorescence studies
Histopathologically, most patients showed either 
subepidermal blisters (Fig. 1 i, j) or liquefaction dege-
neration/oedema in papillary dermis (Fig. 1 k, l) with 
inflammatory infiltration of lymphocytes, eosinophils 
and/or neutrophils. In particular, 9 patients showed no 
apparent subepidermal blister, although inflammatory 
infiltrates were seen in dermis and around dilated 
blood vessels (Fig. 1 m, n). Spongiosis was seen in 12 
patients. No patient showed changes suggesting the 
presence of cutaneous vasculitis, such as leukocyto-
clasis and fibrinoid deposition.
Direct IF for the 20 patients showed granular de-
position of C3 in and just below the BMZ, while no 
depositions of IgG, IgA and IgM were detected (Fig. 
2a). No patient showed C3 deposition in blood vessel 
walls, excluding the presence of cutaneous vasculitis. 
Control BP skin biopsies showed strong linear BMZ 
deposition of C3 and/or IgG (Fig. 2a).
No patients showed positive results in indirect IF 
of either normal human skin or 1M NaCl-split normal 
human skin (data not shown). Complement-fixing IF of 
both normal human skin and 1M NaCl-split normal hu-
man skin also showed negative results (data not shown).
Antigen detection studies for non-dermatitis herpetiformis 
autoimmune bullous diseases
There were no positive results in immunoblot analyses 
for either IgG or IgA antibodies (data not shown). All 
patients also showed negative results in IgG and IgA 
ELISAs for BP230 and BP180 and IgG ELISAs for 
Dsg1 and Dsg3. In additional IgA ELISA for larger 
BP180 ectodomain, none of 19 patients examined sho-
wed definitely positive results, except for borderline 
positive reactivity in 2 patients (Table SI1, right-hand 
column).1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2379
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Serological tests for dermatitis herpetiformis
To exclude the diagnosis of DH, various serological 
tests for DH were also performed for IgA and/or IgG 
antibodies for 19 of the 20 patients (Table SI1). In ge-
neral, the 20 patients showed negative results in these 
studies, although a few patients showed relatively weak 
positive results in several tests.
Thus, both IF of monkey oesophagus and ELISA did 
not detect IgA anti-EMA antibodies in any patients. 
Commercial ELISA for IgA anti-eTG antibodies showed 
positive results in 3 patients. However, its significance is 
obscure, because all sera were negative in another home-
made ELISA for eTG. IgA and IgG ELISAs for tTG, tTG/
DGP and DGP and IgA ELISAs for gliadin and F-actin 
in general showed negative results, except for sporadic 
sera with positive reactivity with low 
titre. Although IgG ELISA for gliadin 
showed positive results in 4 patients, 
the significance was unknown.
Immunofluorescence study for 
various complement components
Next, to determine the complement 
activation pathway in the patient 
skin, we performed IF for various 
complement components using fro-
zen skins from 6 patients. Control 
skin biopsies were also obtained 
from 6 BP patients and 6 normal 
volunteers. These studies used anti-
bodies specific to IgG and C4 for the 
classical activation pathway, Factor 
B for the alternative pathway, MBL 
and ficolins for the lectin pathway, 
and C5–C9 for final stage.
All 6 skin biopsies from the pa-
tients showed negative results for all 
complement components, except for 
positive results for C5–C9 (Fig. 2b, 
Table SIII1). In contrast, all control 
BP skins showed linear BMZ de-
position of C4 and several BP skin 
showed minimum linear deposition 
of factor B, while neither MBL nor 
ficolins deposited in any BP skins. 
Normal skin biopsies showed no 
positive reactivity.
In situ hybridization and qPCR 
studies for C3 production in epidermis
From the results of immunofluo-
rescence for various complement 
components, none of classical, 
alternative and lectin pathways were considered to be 
activated in the patient skin. Therefore, we hypothesi-
zed that C3 deposition is caused by over-production of 
C3 in the epidermis of patient skin. In order to confirm 
this speculation, in situ hybridization and qPCR studies 
were performed for C3 in 4 selected patient skins, 
which were kept at –80°C for 1–4 years.
In situ hybridization with 28S rRNA as positive con-
trol confirmed that the procedure worked well (Fig. 3a). 
Lower expression of C3 mRNA was constantly seen in 
patient epidermis compared with normal control epider-
mis (Fig. 3a). Sense probe for C3 used as negative con-
trol showed no staining in adjacent sections (Fig. 3a).
In qPCR, C3 mRNA expression was also slightly 
lower in patient skins, although statistical significance 
was not achieved (Fig. 3b).
Fig. 1. Dermatitis herpetiformis-like lesions on (a) the buttock and (b) the knees. (c) Vesicles 
and eczematous lesions on the shins. Bullous pemphigoid-like tense blisters on (d) the abdomen 
and (e) palm. (f) Pruriginous lichenification on the back, and annular erythemas without apparent 
blisters on (g) the thigh and (h) waist. Histopathological features (haematoxylin-eosin staining). 
(i, j) Subepidermal blister with inflammatory infiltration. (k, l) Oedema in the upper dermis with 
inflammatory infiltration. (m, n) Perivascular inflammatory infiltration without apparent change 
in the epidermis. Original magnification: (i, m, n) ×100; (j–l) ×200.
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Fig. 3. Studies of expression of C3 mRNA using skin biopsies from 4 patients. (a) The results of in situ hybridization using anti-sense probe, and sense 
probe (negative control) for C3 and positive control probe for 28S rRNA. Positive reaction: blue colour (*). (b) Results of qPCR for expression of C3 in 
the epidermis for 4 normal controls and 4 granular C3 dermatosis (GCD) patients. Error bars = SD.
Fig. 2. Immunofluorescence (IF) studies. (a) Results of initial direct IF examinations. Original magnification: ×100 (upper-left); ×200 (others). (b) Results 
of IF studies of various complement components to clarify involvement of three known complement activating pathways. Original magnification: ×200 
(M-ficolin); ×100 (others). GCD: granular C3 dermatosis; BP: bullous pemphigoid; MBL: mannose-binding lectin A.
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DISCUSSION
This study revealed that the 20 GCD patients had several 
common features; i.e. (i) DH-like clinical features, (ii) 
histopathological features of subepidermal blister/oedema 
and liquefaction degeneration with infiltrations of lympho-
cytes, eosinophils and neutrophils in various combinations, 
(iii) benign disease course with good response to oral 
dapsone and topical steroids, (iv) granular deposition of 
C3 and C5–C9, but not other complement components, 
and (v) slightly reduced expression of C3 in epidermis.
Clearly, we must differentiate GCD from several 
other skin diseases, including various subepidermal 
AIBDs (DH, linear IgA bullous dermatosis, BP and 
epidermolysis bullosa acquisita), cutaneous leukocyto-
clastic vasculitis, porphyria, polymorphous light erup-
tion, pruritic urticarial papules or plaques of pregnancy 
(PUPPP), insect bite and various eczematous diseases.
DH and linear IgA bullous dermatosis show positive 
IgA deposition in BMZ in granular and linear patterns, 
respectively, in direct IF (32). BP and epidermolysis 
bullosa acquisita show IgG autoantibodies to BP230/
BP180 and type VII collagen, respectively, in various 
serological tests (32). Cutaneous leukocytoclastic 
vasculitis shows characteristic histopathological and 
direct IF finding in blood vessels in dermis. Porphyria 
and polymorphous light eruption show skin lesions on 
sun-exposed sites with photosensitivity (33). PUPPP 
should occur in pregnant females (34). However, both 
insect bite and various eczematous diseases may show 
GCD-like features and cannot easily be excluded.
In the present study, no patients showed depositions 
of immunoglobulins and C4, excluding involvement of 
classical pathway for C3 activation. Furthermore, IF 
studies did not show depositions of factor B, mannose-
binding lectin and ficolins, suggesting either the alter-
native or the lectin pathway was involved. Thus, none 
of the known complement activation pathways seemed 
to play a role in deposition of granular C3.
Although the true mechanism for deposition of gra-
nular C3 is unknown, we put forward the following 
5 possibilities. First, that inflammation with heavy 
lymphocytic infiltration in uppermost dermis induced 
deposition of C3 from circulation. However, in contrast 
to deposition of all immunoglobulins and C3 seen in 
lupus erythematosus and other collagen diseases known 
as lupus band test (35), our patients showed exclusive 
C3 deposition. In addition, although lupus band is 
induced by sun-exposure, skin lesions in our patients 
occurred on non-sun-exposed sites.
The 2nd possibility is that immune-complex around 
or inside blood vessels affected by cutaneous vasculitis 
in upper dermis moved to and granularly deposited in 
BMZ by known pathway. However, previous IF study 
of cutaneous vasculitis showed no C3 deposition in 
BMZ (36). In addition, none of our patients showed 
apparent cutaneous vasculitis in both histopathological 
and direct IF studies.
The 3rd possibility is that circulating IgG or IgA 
auto antibodies bound to unknown autoantigen beneath 
BMZ and activated complements. In this case, IgG or 
IgA antibodies could not be detected by direct IF, either 
because the amount of autoantibodies was too low 
or because immunoglobulin deposition was masked. 
However, because no deposition of C1q and C4 was 
shown in IF studies, it was unlikely that the classical 
pathway was activated by binding of immunoglobu-
lins. In addition, although IgA antibodies can activate 
complements via the alternative pathway, our IF study 
also excluded involvement of the alternative pathway. 
The possibility that IgG deposition disappeared more 
quickly than C3 deposition also cannot be completely 
excluded. However, repeated direct IF performed in 3 
patients always showed only C3 deposition, suggesting 
no preceding deposition of IgG.
A 4th possibility is that complements were activated 
by microbes, mannose-containing sugar moieties or 
dead materials via the alternative or the lectin pathway. 
However, as mentioned above, our IF study indicated 
that neither the alternative nor the lectin pathway was 
activated.
Epidermal keratinocytes were reported to produce C3 
on stimulation by various cytokines (37, 38). Therefore, 
the 5th and final possibility is that inflammatory cytoki-
nes upregulated C3 production in the patient skin, and 
over-produced C3 was secreted and deposited in the 
uppermost dermis. However, unexpectedly, the results 
in both in situ hybridization and q-PCR studies for C3 
expression indicated a reduced amount of C3 expres-
sion in the epidermis of our patients. These results do 
not support the 5th possibility.
Thus, future studies are necessary to exclude the 
remaining possibilities, i.e. (i) immunoglobulin(s) and 
complement components for the classical pathway, such 
as C1q and C4, disappeared via a so-far unknown mecha-
nism, (ii) over-expression of C3 by keratinocytes led to a 
reduction in C3 mRNA through negative feedback, and 
(iii) dysregulation of complement activation was induced 
by unknown complement regulators, which are reported 
to activate complement systems erroneously and induce 
abnormal condition in several disorders, including the 
atypical haemolytic uraemic syndrome, systemic lupus 
erythematosus and glomerulonephritis (39).
GCD and classical DH with granular IgA deposition 
show considerably similar clinical features, but different 
histopathological and immunological features. There-
fore, it is necessary to elucidate the pathomechanisms 
of how GCD and DH induce similar clinical features 
through different histopathological and immunological 
changes. The granular pattern of C3 deposition, which 
is a common feature of both GCD and DH, may play a 
role in the same clinical features.
Acta Derm Venereol 96
753Granular C3 dermatosis
Finally, it is currently unknown whether C3 deposi-
tion plays a role in blister formation in GCD. Elucida-
tion of the pathogenic role of C3 deposition in GCD 
should also provide a clue to understanding the patho-
physiology of other subepidermal AIBDs, which show 
C3 deposition, in addition to IgG and/or IgA.
For confirmation of the identity of GCD and the 
patho genic role of granular C3 deposition on BMZ, 
further clinical studies with a large sample of similar 
patients in addition to experimental disease model 
studies are required.
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